Search results
Showing 501 to 550 of 3041 results for all
Palliative care for adults: strong opioids for pain relief (CG140)
This guideline covers safe and effective prescribing of strong opioids for pain relief in adults with advanced and progressive disease. It aims to clarify the clinical pathway for prescribing and help to improve pain management and patient safety. Care during the last 2 to 3 days of life is covered by NICE's guideline on care of dying adults in the last days of life .
Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over (TA1019)
Evidence-based recommendations on crovalimab (Piasky) for paroxysmal nocturnal haemoglobinuria in people 12 years and over.
This quality standard covers identifying and managing familial hypercholesterolaemia (FH) in children, young people and adults. FH is a type of high cholesterol that runs in families and increases the risk of heart disease. The quality standard describes high-quality care in priority areas for improvement.
View quality statements for QS41Show all sections
Sections for QS41
- Quality statements
- Quality statement 1: Diagnosis
- Quality statement 2: Specialist referral
- Quality statement 3: DNA testing
- Quality statement 4: Diagnosis in children under 10 years
- Quality statement 5: Cascade testing
- Quality statement 6: Drug treatment in adults
- Quality statement 7: Drug treatment in children
This quality standard covers interventions to improve the uptake of HIV testing among people who may have undiagnosed HIV. It focuses on increasing testing to reduce undiagnosed infection in people at increased risk of exposure. It describes high-quality care in priority areas for improvement.
View quality statements for QS157Show all sections
Sections for QS157
- Quality statements
- Quality statement 1: Hospitals in areas of high and extremely high HIV prevalence
- Quality statement 2: General practice in areas of high and extremely high HIV prevalence
- Quality statement 3: HIV indicator conditions
- Quality statement 4: Regular HIV testing
- Quality statement 5: People who may have been exposed to HIV
- Update information
- About this quality standard
Training and education of healthcare professionals:- Does ensuring that all hospital healthcare professionals involved in prescribing...
resolution of squamous dysplasia, progression to cancer and quality of life. All complications should be reported, particularly...
This guideline covers diagnosing and managing myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS) in children, young people and adults. It aims to improve awareness and understanding about ME/CFS and when to suspect it, so that people are diagnosed earlier. It includes recommendations on diagnosis, assessment and care planning, safeguarding, access to care and managing ME/CFS and its symptoms.
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating active psoriatic arthritis in adults.
Idelalisib for treating refractory follicular lymphoma (TA604)
Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults.
Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)
Evidence-based recommendations on upadacitinib (Rinvoq) for previously treated moderately to severely active Crohn’s disease in adults.
Evidence-based recommendations on abemaciclib (Verzenios) for treating locally advanced or metastatic, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer in adults who have not had endocrine-based therapy before.
Evidence-based recommendations on imatinib for treating unresectable or metastatic gastrointestinal stromal tumours in adults.
Evidence-based recommendations on faricimab (Vabysmo) for treating visual impairment caused by macular oedema after retinal vein occlusion in adults.
See a complete list of all our guidance and quality standards currently open for consultation
This quality standard covers the additional antenatal care for women who are pregnant with twins or triplets that is offered alongside routine antenatal care. It describes high-quality care in priority areas for improvement.
View quality statements for QS46Show all sections
Sections for QS46
- Quality statements
- Quality statement 1: Determining chorionicity and amnionicity
- Quality statement 2: Labelling the fetuses
- Quality statement 3: Composition of the multidisciplinary core team
- Quality statement 4: Care planning
- Quality statement 5: Monitoring for fetal complications
- Quality statement 6: Involving a consultant from a tertiary level fetal medicine centre
- Quality statement 7: Advice and preparation for preterm birth
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)
Evidence-based recommendations on ponatinib (Iclusig) for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia in adults.
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA1077)
Evidence-based recommendations on nemolizumab (Nemluvio) for treating moderate to severe atopic dermatitis in people 12 years and over.
Evidence-based recommendations on rucaparib (Rubraca) for the maintenance treatment of relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary peritoneal cancer that has completely or partially responded to platinum-based chemotherapy in adults.
This quality standard covers care after emergency treatment for suspected anaphylaxis, including assessment and referral to specialist allergy services. It describes high-quality care in priority areas for improvement.
View quality statements for QS119Show all sections
Sections for QS119
- Quality statements
- Quality statement 1: Initial education in adrenaline auto-injector use
- Quality statement 2: Referral to specialist allergy services after emergency treatment
- Quality statement 3: Specialist assessment for venom immunotherapy
- Quality statement 4: Ongoing training in adrenaline auto-injector use
- Update information
- About this quality standard
Pegaspargase for treating acute lymphoblastic leukaemia (TA408)
Evidence-based recommendations on pegaspargase (Oncaspar) for treating acute lymphoblastic leukaemia.
Evidence-based recommendations on ixekizumab (Taltz) for treating axial spondyloarthritis in adults.
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (MA review of HST12) [ID6145]
In development Reference number: GID-HST10061 Expected publication date: TBC
Brodalumab for treating moderate to severe plaque psoriasis (TA511)
Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults.
Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)
Evidence-based recommendations on ponesimod (Ponvory) for treating relapsing–remitting multiple sclerosis in adults.
View a complete list of all our guidance, NICE advice and quality standards currently in development
Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)
Evidence-based recommendations on eculizumab (Soliris) for treating atypical haemolytic uraemic syndrome in adults and children.
chronic thromboembolic pulmonary hypertension. Details of patient selection, all complications, and subsequent treatments and...
Mirikizumab for treating moderately to severely active ulcerative colitis (TA925)
Evidence-based recommendations on mirikizumab (Omvoh) for treating moderately to severely active ulcerative colitis in adults.
This guideline covers assessing and managing suspected or confirmed cirrhosis in people who are 16 years or older. It aims to improve how cirrhosis is identified and diagnosed, and gives advice on the monitoring, prevention and early management of complications.
Evidence-based recommendations on pembrolizumab (Keytruda) for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.
Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)
Evidence-based recommendations on letermovir (Prevymis) for preventing cytomegalovirus disease after a stem cell transplant.
Ofatumumab for treating relapsing multiple sclerosis (TA699)
Evidence-based recommendations on ofatumumab (Kesimpta) for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features.
This guideline sets out an antimicrobial prescribing strategy for adults with leg ulcer infection. It aims to optimise antibiotic use and reduce antibiotic resistance.
Social anxiety disorder: recognition, assessment and treatment (CG159)
This guideline covers recognising, assessing and treating social anxiety disorder (also known as ‘social phobia’) in children and young people (from school age to 17 years) and adults (aged 18 years and older). It aims to improve symptoms, educational, occupational and social functioning, and quality of life in people with social anxiety disorder.
Evidence-based recommendations on glofitamab (Columvi) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
Evidence-based recommendations on pembrolizumab (Keytruda) for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency in adults.
Technology appraisal submission templates and supporting documents
All the templates and supporting documents you need to make a technology appraisals submission with NICE.
Violent and aggressive behaviours in people with mental health problems (QS154)
This quality standard covers short-term prevention and management of violent and physically threatening behaviour among adults, children and young people with a mental health problem. It applies to settings where mental health, health and social care services are provided. This includes community settings and care received at home. It describes high-quality care in priority areas for improvement.
View quality statements for QS154Show all sections
Sections for QS154
- Quality statements
- Quality statement 1: Identifying triggers and warning signs
- Quality statement 2: Preventing and managing violent or aggressive behaviour
- Quality statement 3: Physical health during and after manual restraint
- Quality statement 4: Physical health after rapid tranquillisation
- Quality statement 5: Immediate post-incident debrief
- About this quality standard
This guideline covers the routine antenatal care that women and their babies should receive. It aims to ensure that pregnant women are offered regular check-ups, information and support.
This quality standard covers diagnosing and managing epilepsies in children, young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS211Show all sections
Sections for QS211
- Quality statements
- Quality statement 1: Referral and assessment after first seizure
- Quality statement 2: Referral to tertiary specialist services
- Quality statement 3: Epilepsy specialist nurse
- Quality statement 4: Epilepsy care plan
- Quality statement 5: Mental health and wellbeing
- Quality statement 6: Neurodevelopment and learning disabilities
- Update information
This quality standard covers routine postnatal care in the first 8 weeks after birth. It describes high-quality care in priority areas for improvement.
View quality statements for QS37Show all sections
Sections for QS37
- Quality statements
- Quality statement 1: Communication between healthcare professionals at transfer of care
- Quality statement 2: Information and advice about babies' feeding
- Quality statement 3: Symptoms and signs of illness in babies
- Quality statement 4: Face-to-face feeding support
- Quality statement 5: Safer practices for bed sharing
- Quality statement 6: GP postnatal check for women
- Quality statement 7: Advice on introducing solid food
Evidence-based recommendations on efanesoctocog alfa (Altuvoct) for treating and preventing bleeding episodes in haemophilia A in people 2 years and over.
Routine antenatal anti-D prophylaxis for women who are rhesus D negative (TA156)
Evidence-based recommendations on routine anti-D prophylaxis for women who are rhesus D negative.
View recommendations for TA156Show all sections
peripheral vascular access devices [VADs] and during dressing changes of all VADs) in reducing VAD-related bacteraemia and VAD site...
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)
Evidence-based recommendations on ertugliflozin (Steglatro) as monotherapy or with metformin for treating type 2 diabetes in adults.
This quality standard covers the mental wellbeing of older people (aged 65 and over) receiving care in care homes (including residential and nursing accommodation, day care and respite care). It focuses on support for people to improve their mental wellbeing so that they can stay as well and independent as possible. It describes high-quality care in priority areas for improvement.
View quality statements for QS50Show all sections
Sections for QS50
- Quality statements
- Quality statement 1: Participation in meaningful activity
- Quality statement 2: Personal identity
- Quality statement 3: Recognition of mental health conditions
- Quality statement 4: Recognition of sensory impairment
- Quality statement 5: Recognition of physical problems
- Quality statement 6: Access to healthcare services
- Update information
Evidence-based recommendations on secukinumab (Cosentyx) for treating active ankylosing spondylitis that has not responded well enough to conventional therapy.
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)
Evidence-based recommendations on asciminib (Scemblix) for chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors.
Evidence-based recommendations on atogepant (Aquipta) for preventing migraine in adults.
Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)
This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.